Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6071748 | 0.91 | PLA2G7 (0.44) | ALDH1A1KMT2ASIGMAR1KDM4E | |
| Trifluoroacetic Acid SCHEMBL6072022 | 0.91 | SLC18A3 (0.44) | SIGMAR1SLC18A3HTR1A | |
| Trifluoroacetic Acid SCHEMBL6071881 | 0.90 | LMNA (0.46) | ALDH1A1LMNAKMT2ASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6072183 | 0.85 | GPR6 (0.50) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6072181 | 0.82 | SLC18A3 (0.56) | LMNAKMT2ASLC18A3 | |
| Trifluoroacetic Acid SCHEMBL3105559 | 0.82 | SLC18A3 (0.60) | ALDH1A1LMNAKMT2ASLC18A3KDM4E | |
| Trifluoroacetic Acid SCHEMBL6072071 | 0.81 | SLC18A3 (0.62) | SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6071601 | 0.81 | LMNA (0.48) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6071855 | 0.80 | SLC18A3 (0.45) | ALDH1A1LMNASLC18A3KDM4EHTR1A | |
| SCHEMBL1256028 | 0.78 | SIGMAR1 (0.49) | ALDH1A1KMT2ASIGMAR1SLC18A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | ALDH1A1 1889/4885LMNA 4727/4885KMT2A 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.